$MRNA
Moderna, Inc. Stock $mrna

$mrna Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000168285221000006 Filed on February 26, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2018
Revenue	$570.7M	$14.06M	$135.1M
YoY Change	3960.48%	-60.32%	-34.38%
Cost Of Revenue	$7.900M		$0.00
YoY Change
Gross Profit	$562.8M		$135.1M
YoY Change
Gross Profit Margin	98.62%		100.0%
Selling, General & Admin	$79.00M	$25.60M	$94.30M
YoY Change	208.59%	-32.63%	45.75%
% of Gross Profit	14.04%		69.82%
Research & Development	$758.9M	$117.5M	$454.1M
YoY Change	545.87%	-21.88%	10.63%
% of Gross Profit	134.84%		336.19%
Depreciation & Amortization	$7.800M	$9.000M	$24.90M
YoY Change	-13.33%	21.62%	21.46%
% of Gross Profit	1.39%		18.44%
Operating Expenses	$837.9M	$144.6M	$548.3M
YoY Change	479.42%	-23.26%	15.39%
Operating Profit	-$275.1M	-$130.6M	-$413.3M
YoY Change	110.71%	-14.69%	53.43%
Interest Expense	$900.0K	$6.200M	$24.00M
YoY Change	-85.48%	3.33%	79.1%
% of Operating Profit
Other Income/Expense, Net	$3.100M	-$400.0K	$1.835M
YoY Change	-875.0%	-107.02%	-197.87%
Pretax Income	-$271.0M	-$123.3M	-$380.5M
YoY Change	119.79%	-12.74%	53.55%
Income Tax	$1.500M	-$200.0K	$326.0K
% Of Pretax Income
Net Earnings	-$272.5M	-$123.1M	-$384.7M
YoY Change	121.36%	-12.94%	50.35%
Net Earnings / Revenue	-47.75%	-875.84%	-284.84%
Basic Earnings Per Share
Diluted Earnings Per Share	-$686.7K	-$368.1K	-$1.170M
COMMON SHARES
Basic Shares Outstanding	395.7M shares	333.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.608B	$1.103B	$1.521B
YoY Change	317.72%	-27.49%	101.24%
Cash & Equivalents	$2.624B	$236.0M	$658.4M
Short-Term Investments	$1.984B	$867.1M	$863.1M
Other Short-Term Assets	$11.00M	$9.000M	$11.00M
YoY Change	22.22%	-18.18%	3.77%
Inventory	$47.00M	$0.00
Prepaid Expenses	$15.65M	$8.475M
Receivables	$1.391B	$5.369M	$12.60M
Other Receivables	$20.00M	$11.00M	$18.00M
Total Short-Term Assets	$6.298B	$1.129B	$1.563B
YoY Change	457.94%	-27.78%	99.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$387.0M	$288.0M	$212.0M
YoY Change	34.38%	35.86%	52.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$639.0M	$160.0M	$173.0M
YoY Change	299.38%	-7.51%	18.57%
Other Assets	$2.000M	$1.931M	$14.20M
YoY Change	3.57%	-26.97%	-13.41%
Total Long-Term Assets	$1.039B	$460.6M	$399.1M
YoY Change	125.57%	15.4%	32.46%
TOTAL ASSETS
Total Short-Term Assets	$6.298B	$1.129B	$1.563B
Total Long-Term Assets	$1.039B	$460.6M	$399.1M
Total Assets	$7.337B	$1.589B	$1.962B
YoY Change	361.61%	-19.0%	80.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.00M	$7.090M	$31.20M
YoY Change	153.88%	-77.28%	50.72%
Accrued Expenses	$470.0M	$67.65M	$79.10M
YoY Change	594.73%	-14.44%	8.8%
Deferred Revenue	$3.867B	$63.31M
YoY Change	6008.04%	-41.95%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$24.00M
YoY Change
Total Short-Term Liabilities	$4.389B	$143.1M	$222.8M
YoY Change	2966.76%	-35.77%	16.34%
LONG-TERM LIABILITIES
Long-Term Debt	$110.0M	$39.00M	$33.50M
YoY Change	182.05%	18.18%	113.38%
Other Long-Term Liabilities	$3.000M	$138.0K	$175.6M
YoY Change	2073.91%	-46.51%	-30.32%
Total Long-Term Liabilities	$3.000M	$138.0K	$209.1M
YoY Change	2073.91%	-46.51%	-21.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.389B	$143.1M	$222.8M
Total Long-Term Liabilities	$3.000M	$138.0K	$209.1M
Total Liabilities	$4.776B	$414.6M	$431.9M
YoY Change	1051.92%	-4.0%	-5.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.244B	-$1.496B
YoY Change	49.95%	48.66%
Common Stock	$0.00	$34.00K
YoY Change	-100.0%	3.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.561B	$1.175B	$1.530B
YoY Change
Total Liabilities & Shareholders Equity	$7.337B	$1.589B	$1.962B
YoY Change	361.61%	-19.0%	80.92%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2018
OPERATING ACTIVITIES
Net Income	-$272.5M	-$123.1M	-$384.7M
YoY Change	121.36%	-12.94%	50.35%
Depreciation, Depletion And Amortization	$7.800M	$9.000M	$24.90M
YoY Change	-13.33%	21.62%	21.46%
Cash From Operating Activities	$1.264B	-$99.10M	-$330.9M
YoY Change	-1375.78%	8.78%	-0.19%
INVESTING ACTIVITIES
Capital Expenditures	-$23.30M	-$6.700M	$105.8M
YoY Change	247.76%	-51.09%	81.1%
Acquisitions
YoY Change
Other Investing Activities	-$166.8M	$137.0M	-$267.3M
YoY Change	-221.75%	591.92%	-156.18%
Cash From Investing Activities	-$190.1M	$130.4M	-$373.1M
YoY Change	-245.78%	2003.23%	-189.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$563.0M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	44.10M	30.80M	$1.227B
YoY Change	43.18%	-94.65%	730163.1%
NET CHANGE
Cash From Operating Activities	1.264B	-99.10M	-$330.9M
Cash From Investing Activities	-190.1M	130.4M	-$373.1M
Cash From Financing Activities	44.10M	30.80M	$1.227B
Net Change In Cash	1.118B	62.10M	$522.9M
YoY Change	1700.81%	-87.35%	507.66%
FREE CASH FLOW
Cash From Operating Activities	$1.264B	-$99.10M	-$330.9M
Capital Expenditures	-$23.30M	-$6.700M	$105.8M
Free Cash Flow	$1.288B	-$92.40M	-$436.6M
YoY Change	-1493.51%	19.38%	11.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001682852
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5063000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-38753
CY2020	dei	Entity Registrant Name EntityRegistrantName	Moderna, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-3467528
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Technology Square
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02139
CY2020	dei	City Area Code CityAreaCode	617
CY2020	dei	Local Phone Number LocalPhoneNumber	714-6500
CY2020	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2020	dei	Trading Symbol TradingSymbol	MRNA
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020Q2	dei	Entity Public Float EntityPublicFloat	25250000000	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	399769582	shares
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4388808000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	143115000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2623850000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235876000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	1983758000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	867124000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1390560000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5369000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	46527000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	252152000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19403000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1032000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1032000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	6297879000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1128804000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	638848000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	159987000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	296889000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	201495000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90201000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	86414000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11053000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10791000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1880000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1931000	USD
CY2020Q4	us-gaap	Assets Assets	7336750000	USD
CY2019Q4	us-gaap	Assets Assets	1589422000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18359000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7090000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	469591000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	67652000	USD
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3867193000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	63310000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33665000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	177419000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	138995000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	97421000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93675000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	109874000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	38689000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1853000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	138000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	4775375000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	414612000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	398787678	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	398787678	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	336536985	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	336536985	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	40000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4801849000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2669426000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3004000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1804000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2243518000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1496454000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2561375000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1174810000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7336750000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1589422000	USD
CY2020	us-gaap	Revenues Revenues	803395000	USD
CY2019	us-gaap	Revenues Revenues	60209000	USD
CY2018	us-gaap	Revenues Revenues	135068000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7933000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1370339000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	496309000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	454082000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	188267000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	109620000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	94252000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	1566539000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	605929000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	548334000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-763144000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-545720000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-413266000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	24715000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	38530000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	27023000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6084000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7526000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1835000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-744513000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-514716000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-384408000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2551000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-695000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	326000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-747064000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514021000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2020	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2019	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2018	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	4127000	USD
CY2020	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2019	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2018	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	12996000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-747064000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-514021000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401857000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.96
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.95
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	381333059	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	330802136	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81114183	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-747064000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514021000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	1148000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2501000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3447000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72565000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-132000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1301000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	323000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	31000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1200000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3124000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-163000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-745864000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-510897000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-384897000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-551365000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1427000	USD
CY2018	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	1833561000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	41322000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	563026000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-163000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1530241000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1530241000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	47259000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2891000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	81122000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	3124000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514021000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1174810000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	1174810000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2120000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1852725000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	179643000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7040000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	93021000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1200000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-747064000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2561375000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-747064000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514021000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	93021000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	81122000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	72565000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31251000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31021000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24862000	USD
CY2020	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	-62286000	USD
CY2019	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	0	USD
CY2018	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	0	USD
CY2020	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-10185000	USD
CY2019	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	3742000	USD
CY2018	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1866000	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-238000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-316000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-891000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1385191000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7216000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-832000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	46527000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	241041000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9751000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5289000	USD
CY2020	mrna	Right Of Use Asset Operating Leases RightOfUseAssetOperatingLeases	10542000	USD
CY2019	mrna	Right Of Use Asset Operating Leases RightOfUseAssetOperatingLeases	5664000	USD
CY2018	mrna	Right Of Use Asset Operating Leases RightOfUseAssetOperatingLeases	0	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11875000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-23964000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15017000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	388392000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3362000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	8787000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3842307000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-44119000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-65260000	USD
CY2020	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	0	USD
CY2019	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	0	USD
CY2018	mrna	Increase Decrease In Deferred Rent Credit IncreaseDecreaseInDeferredRentCredit	2420000	USD
CY2020	mrna	Operating Lease Liabilities OperatingLeaseLiabilities	11792000	USD
CY2019	mrna	Operating Lease Liabilities OperatingLeaseLiabilities	12647000	USD
CY2018	mrna	Operating Lease Liabilities OperatingLeaseLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	5989000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6169000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	910000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2026971000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-458968000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-330865000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	2956295000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1145226000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	1227709000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	1137129000	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	993181000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	783373000	USD
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	214686000	USD
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	168654000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	177008000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	67448000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31554000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105766000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1671928000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14945000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-373094000	USD
CY2020	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	661111000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1852725000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	563026000	USD
CY2020	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	0	USD
CY2018	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	8182000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	179643000	USD
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	47259000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1427000	USD
CY2020	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	7040000	USD
CY2019	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	2891000	USD
CY2018	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	0	USD
CY2020	mrna	Charges To Financing Lease Liabilities ChargesToFinancingLeaseLiabilities	-6215000	USD
CY2019	mrna	Charges To Financing Lease Liabilities ChargesToFinancingLeaseLiabilities	971000	USD
CY2018	mrna	Charges To Financing Lease Liabilities ChargesToFinancingLeaseLiabilities	0	USD
CY2020	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	0	USD
CY2019	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	0	USD
CY2018	mrna	Reimbursement Of Assets From Lease Financing Obligation ReimbursementOfAssetsFromLeaseFinancingObligation	11635000	USD
CY2020	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	0	USD
CY2019	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	0	USD
CY2018	mrna	Payments For Lease Financing Obligation PaymentsForLeaseFinancingObligation	2175000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2033193000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51121000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1226842000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2388236000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-422792000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	522883000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247699000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	670491000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147608000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2635935000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247699000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	670491000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	572000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	416000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	294000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8528000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5585000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2998000	USD
CY2020	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2019	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2018	mrna	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	2638000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17617000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4676000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	12892000	USD
CY2020	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	0	USD
CY2019	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	0	USD
CY2018	mrna	Leasehold Improvements Incurred But Not Yet Reimbursed LeaseholdImprovementsIncurredButNotYetReimbursed	10089000	USD
CY2020	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	0	USD
CY2019	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	0	USD
CY2018	mrna	Lease Financing Obligations Incurred LeaseFinancingObligationsIncurred	10089000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-747100000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514000000.0	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384700000	USD
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	30263158	shares
CY2020Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	17600000	shares
CY2020Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	19.00
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	76.00
CY2020Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	549500000	USD
CY2020Q2	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1300000000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2240000000	USD
CY2020	mrna	Number Of Development Program NumberOfDevelopmentProgram	21	program
CY2016Q3	mrna	Revenue From Grants Number Of Contract Options RevenueFromGrantsNumberOfContractOptions	3	contract_option
CY2020	us-gaap	Use Of Estimates UseOfEstimates	We have made estimates and judgments affecting the amounts reported in our consolidated financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including critical accounting policies or estimates related to revenue recognition, research and development expenses, income tax provisions, stock-based compensation, leases, derivative financial instruments, inventory, and useful lives of long-lived assets. We base our estimates on historical experience and various relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results that we experience may differ materially from our estimates. Significant estimates relied upon in preparing these financial statements include, among others, those related to fair value of equity awards, revenue recognition, research and development expenses, leases, fair value of financial instruments, useful lives of property and equipment, income taxes, and our valuation allowance on our deferred tax assets.
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2623850000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	235876000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1032000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1032000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11053000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10791000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2635935000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	247699000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Financial instruments that subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash, marketable securities, and accounts receivable. Our investment portfolio comprises money market funds, marketable debt securities, including U.S. Treasury securities, debt securities of U.S. government agencies and corporate entities and commercial paper. Our cash management and investment policy limits investment instruments to investment-grade securities with the objective to preserve capital and to maintain liquidity until the funds can be used in business operations. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC limits.
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	87225000	USD
CY2020	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	-7100000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	1980963000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1983758000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	637382000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	638848000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2618345000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	2622606000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	864958000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	867124000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	159148000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	159987000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1024106000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	1027111000	USD
CY2020	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	152000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	588540000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	108	security
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	19	security
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	152000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	588540000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	40000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	85161000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	40000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	85161000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	36222000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9015000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1290000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	46527000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	416550000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	296079000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	119661000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	94584000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	296889000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	201495000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31300000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31000000.0	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24900000	USD
CY2020Q4	mrna	Other Prepaid Expense Manufacturing OtherPrepaidExpenseManufacturing	216538000	USD
CY2019Q4	mrna	Other Prepaid Expense Manufacturing OtherPrepaidExpenseManufacturing	0	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	15647000	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8475000	USD
CY2020Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	10242000	USD
CY2019Q4	mrna	Tenant Incentives Receivables Current TenantIncentivesReceivablesCurrent	4093000	USD
CY2020Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	9725000	USD
CY2019Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	6835000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	252152000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19403000	USD
CY2020Q4	mrna	Accrued Clinical Trials AccruedClinicalTrials	97249000	USD
CY2019Q4	mrna	Accrued Clinical Trials AccruedClinicalTrials	6291000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	95247000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27428000	USD
CY2020Q4	mrna	Raw Materials Accounts Payable RawMaterialsAccountsPayable	78085000	USD
CY2019Q4	mrna	Raw Materials Accounts Payable RawMaterialsAccountsPayable	0	USD
CY2020Q4	mrna	Accrued Manufacturing AccruedManufacturing	53412000	USD
CY2019Q4	mrna	Accrued Manufacturing AccruedManufacturing	5872000	USD
CY2020Q4	mrna	Accrued Development Operation AccruedDevelopmentOperation	29253000	USD
CY2019Q4	mrna	Accrued Development Operation AccruedDevelopmentOperation	2567000	USD
CY2020Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	17576000	USD
CY2019Q4	mrna	Accrued Property And Equipment Current AccruedPropertyAndEquipmentCurrent	4029000	USD
CY2020Q4	mrna	Commercial Commercial	6922000	USD
CY2019Q4	mrna	Commercial Commercial	0	USD
CY2020Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	91847000	USD
CY2019Q4	mrna	Accrued External Goods And Services Current AccruedExternalGoodsAndServicesCurrent	21465000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	469591000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	67652000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24328000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5972000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3583000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	3365000	USD
CY2019Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1480000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33665000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5063000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	202305000	USD
CY2020	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	4009960000	USD
CY2020	mrna	Contract With Customer Liability Deductions During Period ContractWithCustomerLiabilityDeductionsDuringPeriod	167653000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4044612000	USD
CY2020Q4	mrna	Operating Lease Number Of Properties OperatingLeaseNumberOfProperties	2	campus
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	90201000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	86414000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	55045000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9544000	USD
CY2020Q4	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	145246000	USD
CY2019Q4	mrna	Operating And Finance Lease Right Of Use Asset OperatingAndFinanceLeaseRightOfUseAsset	95958000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5972000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3583000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24328000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0	USD
CY2020Q4	mrna	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	30300000	USD
CY2019Q4	mrna	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	3583000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	97421000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	93675000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	109874000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	38689000	USD
CY2020Q4	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	207295000	USD
CY2019Q4	mrna	Operating And Finance Lease Liability Noncurrent OperatingAndFinanceLeaseLiabilityNoncurrent	132364000	USD
CY2020Q4	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	237595000	USD
CY2019Q4	mrna	Operating And Finance Lease Liability OperatingAndFinanceLeaseLiability	135947000	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13322000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	16939000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	17015000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1011000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	309000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	9891000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	6557000	USD
CY2020	mrna	Finance Lease Cost FinanceLeaseCost	10902000	USD
CY2019	mrna	Finance Lease Cost FinanceLeaseCost	6866000	USD
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	5229000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	4399000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	19100000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	15089000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	16121000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	8523000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	5585000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	7519000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	USD
CY2020	mrna	Right Of Use Assets Reduced Through Lease Modifications And Reassessments RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments	6755000	USD
CY2019	mrna	Right Of Use Assets Reduced Through Lease Modifications And Reassessments RightOfUseAssetsReducedThroughLeaseModificationsAndReassessments	2717000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	17107000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	34014000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	46495000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0	USD
CY2020	mrna	Lessee Finance Lease Expense LesseeFinanceLeaseExpense	1304000	USD
CY2019	mrna	Lessee Finance Lease Expense LesseeFinanceLeaseExpense	971000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P25Y
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.103
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.131
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	15492000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	36579000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	15913000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	11848000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	16008000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	12054000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	16168000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	12279000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	16567000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	12493000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	93599000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	428059000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	173747000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	513312000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	70354000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	379110000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	103393000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	134202000	USD
CY2017Q2	mrna	Research And Development Arrangement Contract To Perform For Others Commercial Milestones Maximum Amount ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount	24000000.0	USD
CY2020	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	6900000	USD
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	775000000	shares
CY2018Q2	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	509352795	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1600000000	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	162000000	shares
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	64200000	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	45536915	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.82
CY2019Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	7.35
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	13888434	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.93
CY2020	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	6.68
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	286310000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	5036520	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	36.04
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.30
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2627468	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	18.14
CY2020	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageGrantDateFairValue	10.56
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	34057533	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.14
CY2020Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	9.12
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2976235000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17461374	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.99
CY2020Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	5.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1632365000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	16596159	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	23.61
CY2020Q4	mrna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue	12.75
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y2M12D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1343870000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	785700000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	75600000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5300000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	179600000	USD
CY2020	us-gaap	Restricted Stock Expense RestrictedStockExpense	5000000.0	USD
CY2019	us-gaap	Restricted Stock Expense RestrictedStockExpense	5500000	USD
CY2018	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	93021000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81122000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72565000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	93021000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81122000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72565000	USD
CY2020Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	226800000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5000000.0	USD
CY2020	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.06
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4200000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2100000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-745445000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-508595000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-380473000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	932000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6121000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-3935000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-744513000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-514716000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-384408000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-26000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	32000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	505000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	352000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2519000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1200000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2551000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	505000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	326000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1200000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2551000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-695000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	326000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	587211000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	268173000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	33089000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	43978000	USD
CY2020Q4	mrna	Deferred Tax Assets Capitalized Licenses Research And Development And Start Up Costs DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts	13985000	USD
CY2019Q4	mrna	Deferred Tax Assets Capitalized Licenses Research And Development And Start Up Costs DeferredTaxAssetsCapitalizedLicensesResearchAndDevelopmentAndStartUpCosts	19891000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	99024000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	874100000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	141000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	77222000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	26962000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7377000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	29785000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	53475000	USD
CY2020Q4	mrna	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	22313000	USD
CY2019Q4	mrna	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	26571000	USD
CY2020Q4	mrna	Deferred Tax Assets Financing Lease Liability DeferredTaxAssetsFinancingLeaseLiability	23718000	USD
CY2019Q4	mrna	Deferred Tax Assets Financing Lease Liability DeferredTaxAssetsFinancingLeaseLiability	10570000	USD
CY2020Q4	mrna	Deferred Tax Assets Deferred Expense Capitalized Inventory Costs DeferredTaxAssetsDeferredExpenseCapitalizedInventoryCosts	38058000	USD
CY2019Q4	mrna	Deferred Tax Assets Deferred Expense Capitalized Inventory Costs DeferredTaxAssetsDeferredExpenseCapitalizedInventoryCosts	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	874145000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	507268000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	823468000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-747064000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-514021000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-384734000	USD
CY2020	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	470753000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	50677000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	36515000	USD
CY2020Q4	mrna	Deferred Tax Liabilities Finance Lease Right Of Use Asset DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset	11539000	USD
CY2019Q4	mrna	Deferred Tax Liabilities Finance Lease Right Of Use Asset DeferredTaxLiabilitiesFinanceLeaseRightOfUseAsset	2612000	USD
CY2020Q4	mrna	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	20349000	USD
CY2019Q4	mrna	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	24944000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	18276000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	8959000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	513000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	50677000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	36515000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	352700000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.063
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.036
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.016
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.474
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.330
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.285
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.038
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.025
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.015
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.198
CY2018	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	4127000	USD
CY2020	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2019	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0	USD
CY2019	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2018	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	12996000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-747064000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-514021000	USD
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-401857000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	381333059	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	330802136	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81114183	shares
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.96
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.95
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36250493	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46714164	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	51478444	shares
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Revenues Revenues	803395000	USD
CY2019	us-gaap	Revenues Revenues	60209000	USD
CY2018	us-gaap	Revenues Revenues	135068000	USD

Files In Submission

Name	View Source	Status
0001682852-21-000006-index-headers.html	Edgar Link	pending
0001682852-21-000006-index.html	Edgar Link	pending
0001682852-21-000006.txt	Edgar Link	pending
0001682852-21-000006-xbrl.zip	Edgar Link	pending
a2312020consentforincorpra.htm	Edgar Link	pending
exhibit1017moderna.htm	Edgar Link	pending
exhibit1027supplycontrac.htm	Edgar Link	pending
exhibit1027supplycontrac001.jpg	Edgar Link	pending
exhibit1027supplycontrac002.jpg	Edgar Link	pending
exhibit1027supplycontrac003.jpg	Edgar Link	pending
exhibit1027supplycontrac004.jpg	Edgar Link	pending
exhibit1027supplycontrac005.jpg	Edgar Link	pending
exhibit1027supplycontrac006.jpg	Edgar Link	pending
exhibit1027supplycontrac007.jpg	Edgar Link	pending
exhibit1027supplycontrac008.jpg	Edgar Link	pending
exhibit1027supplycontrac009.jpg	Edgar Link	pending
exhibit1027supplycontrac010.jpg	Edgar Link	pending
exhibit1027supplycontrac011.jpg	Edgar Link	pending
exhibit1027supplycontrac012.jpg	Edgar Link	pending
exhibit1027supplycontrac013.jpg	Edgar Link	pending
exhibit1027supplycontrac014.jpg	Edgar Link	pending
exhibit1027supplycontrac015.jpg	Edgar Link	pending
exhibit1027supplycontrac016.jpg	Edgar Link	pending
exhibit1027supplycontrac017.jpg	Edgar Link	pending
exhibit1027supplycontrac018.jpg	Edgar Link	pending
exhibit1027supplycontrac019.jpg	Edgar Link	pending
exhibit1027supplycontrac020.jpg	Edgar Link	pending
exhibit1027supplycontrac021.jpg	Edgar Link	pending
exhibit1027supplycontrac022.jpg	Edgar Link	pending
exhibit1027supplycontrac023.jpg	Edgar Link	pending
exhibit1027supplycontrac024.jpg	Edgar Link	pending
exhibit1027supplycontrac025.jpg	Edgar Link	pending
exhibit1027supplycontrac026.jpg	Edgar Link	pending
exhibit1027supplycontrac027.jpg	Edgar Link	pending
exhibit1027supplycontrac028.jpg	Edgar Link	pending
exhibit1027supplycontrac029.jpg	Edgar Link	pending
exhibit1027supplycontrac030.jpg	Edgar Link	pending
exhibit1027supplycontrac031.jpg	Edgar Link	pending
exhibit21subsidiaries1.htm	Edgar Link	pending
exhibit31112312020.htm	Edgar Link	pending
exhibit31212312020.htm	Edgar Link	pending
exhibit32112312020.htm	Edgar Link	pending
exhibit32212312020.htm	Edgar Link	pending
exhibit4312312020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrna-20201231.htm	Edgar Link	pending
mrna-20201231.xsd	Edgar Link	pending
mrna-20201231_cal.xml	Edgar Link	unprocessable
mrna-20201231_def.xml	Edgar Link	unprocessable
mrna-20201231_g1.jpg	Edgar Link	pending
mrna-20201231_g10.jpg	Edgar Link	pending
mrna-20201231_g11.jpg	Edgar Link	pending
mrna-20201231_g12.jpg	Edgar Link	pending
mrna-20201231_g13.jpg	Edgar Link	pending
mrna-20201231_g14.jpg	Edgar Link	pending
mrna-20201231_g15.jpg	Edgar Link	pending
mrna-20201231_g16.jpg	Edgar Link	pending
mrna-20201231_g17.jpg	Edgar Link	pending
mrna-20201231_g18.jpg	Edgar Link	pending
mrna-20201231_g19.jpg	Edgar Link	pending
mrna-20201231_g2.jpg	Edgar Link	pending
mrna-20201231_g20.jpg	Edgar Link	pending
mrna-20201231_g21.jpg	Edgar Link	pending
mrna-20201231_g22.jpg	Edgar Link	pending
mrna-20201231_g23.jpg	Edgar Link	pending
mrna-20201231_g24.jpg	Edgar Link	pending
mrna-20201231_g25.jpg	Edgar Link	pending
mrna-20201231_g26.jpg	Edgar Link	pending
mrna-20201231_g27.jpg	Edgar Link	pending
mrna-20201231_g28.jpg	Edgar Link	pending
mrna-20201231_g29.jpg	Edgar Link	pending
mrna-20201231_g3.jpg	Edgar Link	pending
mrna-20201231_g30.jpg	Edgar Link	pending
mrna-20201231_g31.jpg	Edgar Link	pending
mrna-20201231_g32.jpg	Edgar Link	pending
mrna-20201231_g33.jpg	Edgar Link	pending
mrna-20201231_g34.jpg	Edgar Link	pending
mrna-20201231_g35.jpg	Edgar Link	pending
mrna-20201231_g36.jpg	Edgar Link	pending
mrna-20201231_g37.jpg	Edgar Link	pending
mrna-20201231_g38.jpg	Edgar Link	pending
mrna-20201231_g39.jpg	Edgar Link	pending
mrna-20201231_g4.jpg	Edgar Link	pending
mrna-20201231_g40.jpg	Edgar Link	pending
mrna-20201231_g41.jpg	Edgar Link	pending
mrna-20201231_g42.gif	Edgar Link	pending
mrna-20201231_g43.gif	Edgar Link	pending
mrna-20201231_g44.gif	Edgar Link	pending
mrna-20201231_g45.jpg	Edgar Link	pending
mrna-20201231_g46.jpg	Edgar Link	pending
mrna-20201231_g5.jpg	Edgar Link	pending
mrna-20201231_g6.jpg	Edgar Link	pending
mrna-20201231_g7.jpg	Edgar Link	pending
mrna-20201231_g8.jpg	Edgar Link	pending
mrna-20201231_g9.jpg	Edgar Link	pending
mrna-20201231_htm.xml	Edgar Link	completed
mrna-20201231_lab.xml	Edgar Link	unprocessable
mrna-20201231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRNA
Moderna, Inc. Stock $mrna

2020 Q4 Form 10-K Financial Statement

#000168285221000006 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA Moderna, Inc. Stock $mrna

2020 Q4 Form 10-K Financial Statement

#000168285221000006 Filed on February 26, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRNA
Moderna, Inc. Stock $mrna